Statement On Lower Insulin Costs From Building Back Together
FOR IMMEDIATE RELEASE: March 16, 2023
PRESS CONTACT: [email protected]
STATEMENT ON LOWER INSULIN COSTS FROM BUILDING BACK TOGETHER
WASHINGTON, D.C. — Building Back Together released the following statement after Sanofi announced they will cap the cost of insulin at $35 a month, becoming the last of the three major insulin manufacturers to heed President Biden’s call to lower prescription drug prices:
“I have lived with Type 1 Diabetes for over 22 years. I never believed I would see the day when I could afford the insulin I need to stay alive without health insurance — but that day is here,” said Building Back Together spokesperson Eileen Garcia. “No one should have to choose between the medication they need to stay alive and paying their rent or putting food on the table. This has been the reality for insulin-dependent diabetics in America for far too long.”
Today’s announcement follows significant actions President Biden has taken to lower the cost of prescription drugs, including insulin. The Inflation Reduction Act President Biden signed last year – that no Republican in Congress voted for – capped the cost of insulin at $35 a month for Medicare recipients, and in his State of the Union, he called on Big Pharma companies to finish the job and cap insulin costs for all people. With today’s announcement, the three largest insulin manufacturers in the country have answered his call.